| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE42353 | GENZYME CORP | Quinazoline derivatives and pharmaceutical compositions containing them |
Jun, 2022
(1 year, 3 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8642608 | GENZYME CORP | Quinazoline derivatives as VEGF inhibitors |
Feb, 2022
(1 year, 7 months ago) | |
| US8067427 | GENZYME CORP | Pharmaceutical compositions comprising ZD6474 |
Aug, 2028
(4 years from now) | |
Caprelsa is owned by Genzyme Corp.
Caprelsa contains Vandetanib.
Caprelsa has a total of 3 drug patents out of which 2 drug patents have expired.
Expired drug patents of Caprelsa are:
- US8642608
- USRE42353
Caprelsa was authorised for market use on 06 April, 2011.
Caprelsa is available in tablet;oral dosage forms.
Caprelsa can be used as for use in patients having symptomatic or progressive medullary thyroid cancer, with unresectable locally advanced or metastatic disease.
The generics of Caprelsa are possible to be released after 08 August, 2028.
Drugs and Companies using VANDETANIB ingredient
Market Authorisation Date: 06 April, 2011
Treatment: For use in patients having symptomatic or progressive medullary thyroid cancer, with unresectable locally advanced or metastatic disease
Dosage: TABLET;ORAL
CAPRELSA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic